Vancomycin or Fidaxomicin

Phase 3Small molecule

Vancomycin or Fidaxomicin is one of 13 small molecule programs targeting Clostridium Difficile Infection. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clostridium Difficile InfectionActive, not recruiting

Clostridioides Difficile InfectionRecruiting

Clostridium Difficile InfectionPreclinical

Active, not recruiting

Clostridioides Difficile InfectionPhase 3

Recruiting

Competition

Competitive Landscape

10 competitors in Clostridium Difficile Infection

#DrugCompanyPhaseTrials

Dificlir

Merck & Co.

Approved

10 2

Vancocin

HHikma Pharmaceuticals LLC

Approved

21 3

ZINPLAVA

Merck & Co.

Approved

4 4

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

—5

Vancomycin or Fidaxomicin

SSejtterapia Kozpont Kft.

Phase 3

1 6

Stools

VVersailles Hospital

Preclinical

1 7

Serum

VVersailles Hospital

Preclinical

1 8

Whole Blood

VVersailles Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Clostridioides Difficile Infection

NCT05266807

Clinical

Trials by Indication[1]

Clostridium Difficile Infection1 trial

A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile Infection

Unknown status·SSejtterapia Kozpont Kft.·N/A·NCT03053505·150 enrolled

Clostridioides difficile Infection1 trial

Fecal Microbiota Transplantation Versus Vancomycin or Fidaxomicin in Clostridioides Difficile Infection First Episode or First Recurrence: A Randomized Controlled, Open-label, Multicenter Phase III Clinical Trial

Recruiting·BBenoit Guery·Phase 3·NCT05266807·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Vancomycin or Fidaxomicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vancomycin or Fidaxomicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vancomycin or Fidaxomicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sejtterapia Kozpont Kft. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSejtterapia Kozpont Kft.

Vancomycin or Fidaxomicin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Clostridium Difficile Infection1 trial

Clostridioides difficile Infection1 trial

References

Drug Info

Quick Facts

Related News